Rhumbline Advisers Compass Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 131,789 shares of CMPX stock, worth $241,173. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,789
Previous 119,474
10.31%
Holding current value
$241,173
Previous $236,000
44.49%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CMPX
# of Institutions
84Shares Held
92.7MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$40.9 Million0.54% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$20.4 Million0.02% of portfolio
-
Blackstone Inc New York, NY7.69MShares$14.1 Million0.03% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$12.1 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD5.51MShares$10.1 Million0.17% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $185M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...